Alignment Healthcare Inc (NASDAQ:ALHC) shares are soaring on Tuesday after the Centers for Medicare & Medicaid Services announced a 2.48% rate hike for 2027 Medicare Advantage and Part D programs.
- Alignment Healthcare stock is surging to new heights today. What’s fueling ALHC momentum?
The U.S. government confirmed it will raise 2027 Medicare Advantage and Part D payments by an average of 2.48%, Reuters reported. CMS officials also said insurers will receive an additional 2.5% uplift tied to adjustments in risk‑scoring formulas, bringing the effective increase to roughly 5%. In dollar terms, CMS estimates the final rule will push more than $13 billion in extra funding into Medicare Advantage plans.
That’s a dramatic turnaround from the January draft, which proposed essentially flat reimbursement and triggered a sector‑wide selloff.
Why Insurers Are Calling This A Win
The jump from 0.09% to 2.48% — plus the added 2.5% tied to risk adjustment — is being viewed as a clear victory for insurers who argued the earlier proposal didn’t reflect rising medical costs. Morningstar’s Julie Utterback said the final rule gives carriers a more realistic framework for modeling 2027 medical expenses.
Kevin Gade of Bahl and Gaynor went even further, estimating that once all methodology tweaks are included, the real‑world increase may land closer to 3.5%–4%. He described the outcome simply: “a win.”
CMS Hits Pause On Risk‑Model Changes To Avoid Market Disruption
Regulators also decided to delay certain risk‑model changes that insurers said would be destabilizing if implemented too quickly. CMS acknowledged that some carriers had already begun dropping capitated plans — arrangements that pay a fixed amount per member — and that some providers had exited Medicare Advantage networks.
Alignment Technical Analysis
At $22.12, the stock is trading 25.7% above its 20-day simple moving average (SMA), the stock’s average price over the last 20 sessions, which suggests short-term trend control has shifted back to buyers. It’s also 13.9% above its 100-day SMA, indicating the intermediate trend is still leaning upward despite recent volatility.
Moving average convergence divergence (MACD), a trend/momentum measure, is bullish with the MACD at -0.3547 above the signal line at -0.6062, which suggests downside pressure has been fading. That said, the 20-day SMA remains below the 50-day SMA, a reminder that the shorter-term trend only recently started improving.
- Key Resistance: $23.50 — a level where rallies have recently stalled.
- Key Support: $20.00 — an area where buyers have tended to step in.
Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $19.22. Recent analyst moves include:
- JP Morgan: Overweight (Raises Target to $26.00) (Feb. 5)
- TD Cowen: Buy (Raises Target to $25.00) (Jan. 16)
- UBS: Neutral (Raises Target to $21.00) (Jan. 14)
Benzinga Edge Rankings: The Benzinga Edge scorecard for Alignment highlights its strengths and weaknesses compared to the broader market.
- Momentum: Neutral (Score: 32.78) — The trend is improving, but the score suggests it’s not a broad market leader yet.
- Value: Weak (Score: 7.05) — The stock screens poorly on value metrics versus peers, implying a premium setup.
The Verdict: Alignment’s Benzinga Edge signal reveals a momentum-improving profile paired with a weak value score. That combination often fits a “pay for growth/turnaround” setup, where execution and upcoming catalysts matter more than cheapness.
ALHC Price Action: Alignment shares were up 19.44% at $22.30 at the time of publication on Tuesday, according to Benzinga Pro.
Image: Miha Creative/Shutterstock
Recent Comments